Microbiota Intervention for Parkinson's Disease
(MICRO-PD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to help people with Parkinson's disease by using antibiotics to change their gut bacteria. This could make their medications work better and reduce symptoms. Researchers will study how these changes affect patients' symptoms and overall health.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it requires participants to be stable on levodopa therapy. This suggests you may need to continue your current levodopa treatment.
Is rifaximin safe for use in humans?
Rifaximin, a nonabsorbable antibiotic, has been studied for its effects on gut microbiota and inflammation in Parkinson's disease. The studies suggest that rifaximin is generally well-tolerated and safe, with potential benefits in reducing inflammation and improving motor symptoms in Parkinson's patients.12345
How does the drug Rifaximin differ from other treatments for Parkinson's disease?
What data supports the effectiveness of the drug Rifaximin for Parkinson's Disease?
Who Is on the Research Team?
Caroline Tanner, MD, PhD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Cross-sectional Analysis
Correlate the microbiome profile with the clinical phenotype of PD and medication response
Randomized Controlled Trial
Evaluate the effect of microbiome manipulation on clinical phenotype and medication response
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Rifaximin
Rifaximin is already approved in United States, Canada, European Union, India for the following indications:
- Traveler's diarrhea
- Irritable bowel syndrome with diarrhea
- Hepatic encephalopathy
- Traveler's diarrhea
- Irritable bowel syndrome with diarrhea
- Hepatic encephalopathy
- Traveler's diarrhea
- Irritable bowel syndrome with diarrhea
- Hepatic encephalopathy
- Traveler's diarrhea
- Irritable bowel syndrome with diarrhea
- Hepatic encephalopathy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
Nova Southeastern University
Collaborator
Gateway Institute for Brain Research
Industry Sponsor